(redirected from Vioxx Gastrointestinal Outcomes Research)
VIGORVioxx Gastrointestinal Outcomes Research
VIGORVegetarian Information Group of Rochester (Rochester, MN)
VIGORVolunteers in Government of Responsibility (New Orleans, LA)
References in periodicals archive ?
Trial names used in this review ADAPT: Alzheimer's Disease Anti-inflammatory Prevention Trial APC: Adenoma Prevention with Celecoxib APPROVe: Adenomatous Polyp Prevention on Vioxx CLASS: Celecoxib Long-term Arthritis Safety Study MEDAL programme: Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme PreSAP: Prevention of colorectal Spontaneous Adenomatous Polyps TARGET: Therapeutic Arthritis Research and Gastrointestinal Event Trial VIGOR: Vioxx Gastrointestinal Outcomes Research Table II.
In the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial, 8,076 rheumatoid arthritis patients were randomized to rofecoxib 50 mg/day or naproxen 1,000 mg/day.
s Vioxx (rofecoxib) to include results from the landmark 8,000-patient Vioxx Gastrointestinal Outcomes Research (VIGOR) study.